Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study

Huang,Zhi‑Liang; Cao,Xun; Luo,Ruo‑Zhen; Chen,You‑Fang; Zhu,Lin‑Chun; Wen,Zhesheng

doi:10.3892/ol.2015.3894

Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study

Authors:
- Zhi‑Liang Huang
- Xun Cao
- Ruo‑Zhen Luo
- You‑Fang Chen
- Lin‑Chun Zhu
- Zhesheng Wen
View Affiliations

Affiliations: Department of Thoracic Oncology, Sun Yat‑Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China, Graceland Medical Centre, The Sixth Affiliated Hospital of Sun Yat‑Sen University, Guangzhou, Guangdong 510623, P.R. China
Published online on: November 9, 2015 https://doi.org/10.3892/ol.2015.3894
Pages: 299-305

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although adjuvant platinum-based chemotherapy has been demonstrated to improve survival in patients with completely resected non‑small cell lung cancer (NSCLC), individualized approaches to therapy are urgently required to improve the treatment efficacy and reduce unnecessary toxicity. It was hypothesized in the present study that the protein levels of excision repair cross‑complementation group 1 (ERCC1), breast cancer 1 (BRCA1), ribonucleotide reductase M1 (RRM1) and class III β‑tubulin (TUBB3) may influence the therapeutic effect of adjuvant cisplatin‑based chemotherapy. The expression of ERCC1, BRCA1, RRM1 and TUBB3 in tissues obtained from 84 patients with NSCLC was analyzed in the present non‑interventional study by immunohistochemistry prior to adjuvant chemotherapy. All patients received adjuvant cisplatin‑based chemotherapy. The primary endpoint in the present study was disease free survival (DFS). Out of the 84 tumors, the expression of ERCC1, BRCA1, RRM1 and TUBB3 was identified in 46 (55%), 11 (13%), 73 (87%) and 76 (90%) tissues, respectively. A beneficial response to adjuvant cisplatin‑based chemotherapy in DFS was associated with the absence of the expression of ERCC1 [hazard ratio (HR), 2.166; 95% confidence interval (CI), 1.049‑4.474; P=0.037] and BRCA1 (HR, 2.419; 95% CI, 1.127‑5.193; P=0.023), but not with the expression status of RRM1 (HR, 0.568; 95% CI, 0.234‑1.379; P=0.212) or TUBB3 (HR, 1.874; 95% CI, 0.448‑7.842; P=0.39). In addition, patients lacking the expression of ERCC1 and BRCA1 benefited more from adjuvant cisplatin‑based chemotherapy compared with patients that expressed either ERCC1 or BRCA1 (HR, 3.102; 95% CI, 1.343‑7.163; P=0.008). The expression of ERCC1 and BRCA1 was significantly associated with the DFS time in patients with NSCLC treated with adjuvant cisplatin‑based chemotherapy, respectively. The combination of the ERCC1 and BRCA1 expression levels may be a promising prognostic prediction for adjuvant cisplatin-based chemotherapy.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Lozano R, Naghavi M, Foreman K, et al: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 380:2095–2128. 2012. View Article : Google Scholar : PubMed/NCBI
3	Devesa SS, Bray F, Vizcaino AP and Parkin DM: International lung cancer trends by histologic type: Male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 117:294–299. 2005. View Article : Google Scholar : PubMed/NCBI
4	NSCLC Meta-analyses Collaborative Group. Arriagada R, Auperin A, Burdett S, et al: Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: Two meta-analyses of individual patient data. Lancet. 375:1267–1277. 2010. View Article : Google Scholar : PubMed/NCBI
5	Pignon JP, Tribodet H, Scagliotti GV, et al: LACE Collaborative Group: Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol. 26:3552–3559. 2008. View Article : Google Scholar : PubMed/NCBI
6	Reck M, Heigener DF, Mok T, Soria JC and Rabe KF: Management of non-small-cell lung cancer: recent developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
7	Olaussen KA, Dunant A, Fouret P, et al: IALT Bio Investigators: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 355:983–991. 2006. View Article : Google Scholar : PubMed/NCBI
8	Vilmar A and Sørensen JB: Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: A review of current literature. Lung Cancer. 64:131–139. 2009. View Article : Google Scholar : PubMed/NCBI
9	Reed E: Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev. 24:331–344. 1998. View Article : Google Scholar : PubMed/NCBI
10	Simon GR, Ismail-Khan R and Bepler G: Nuclear excision repair-based personalized therapy for non-small cell lung cancer: From hypothesis to reality. Int J Biochem Cell Biol. 39:1318–1328. 2007. View Article : Google Scholar : PubMed/NCBI
11	Quinn JE, James CR, Stewart GE, et al: BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res. 13:7413–7420. 2007. View Article : Google Scholar : PubMed/NCBI
12	Taron M, Rosell R, Felip E, et al: BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet. 13:2443–2449. 2004. View Article : Google Scholar : PubMed/NCBI
13	Mann GJ, Musgrove EA, Fox RM and Thelander L: Ribonucleotide reductase M1 subunit in cellular proliferation, quiescence, and differentiation. Cancer Res. 48:5151–5156. 1988.PubMed/NCBI
14	Engström Y, Eriksson S, Jildevik I, Skog S, Thelander L and Tribukait B: Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits. J Biol Chem. 260:9114–9116. 1985.PubMed/NCBI
15	Jordan MA, Toso RJ, Thrower D and Wilson L: Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA. 90:9552–9556. 1993. View Article : Google Scholar : PubMed/NCBI
16	Sève P, Isaac S, Trédan O, et al: Expression of class III β-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res. 11:5481–5486. 2005. View Article : Google Scholar : PubMed/NCBI
17	Bepler G, Williams C, Schell MJ, et al: Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 31:2404–2412. 2013. View Article : Google Scholar : PubMed/NCBI
18	Tiseo M, Bordi P, Bortesi B, Boni C, et al: Bio-FAST trial group: ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer. 108:1695–1703. 2013. View Article : Google Scholar : PubMed/NCBI
19	Booton R, Ward T, Ashcroft L, Morris J, Heighway J and Thatcher N: ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol. 2:902–906. 2007. View Article : Google Scholar : PubMed/NCBI
20	Cobo M, Isla D, Massuti B, et al: Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A phase III trial in non-small-cell lung cancer. J Clin Oncol. 25:2747–2754. 2007. View Article : Google Scholar : PubMed/NCBI
21	Sobin LH, Gospodarowicz MK and Wittekind C: Lung and Pleural Tumors. TNM Classification of Malignant Tumors (7th). (Hoboken, NJ). Wiley-Blackwell. 136–148. 2010.
22	Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP and Vansteenkiste J: International Adjuvant Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 350:351–360. 2004. View Article : Google Scholar : PubMed/NCBI
23	Douillard JY, Rosell R, De Lena M, et al: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial. Lancet Oncol. 7:719–727. 2006. View Article : Google Scholar : PubMed/NCBI
24	Mu D, Hsu DS and Sancar A: Reaction mechanism of human DNA repair excision nuclease. J Biol Chem. 271:8285–8294. 1996. View Article : Google Scholar : PubMed/NCBI
25	Zamble DB, Mu D, Reardon JT, Sancar A and Lippard SJ: Repair of cisplatin - DNA adducts by the mammalian excision nuclease. Biochemistry. 35:10004–10013. 1996. View Article : Google Scholar : PubMed/NCBI
26	De Silva IU, McHugh PJ, Clingen PH and Hartley JA: Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol. 20:7980–7990. 2000. View Article : Google Scholar : PubMed/NCBI
27	Lian S, Su H, Zhao BX, Liu WY, Zheng LW and Miao JY: Synthesis and discovery of pyrazole-5-carbohydrazide N-glycosides as inducer of autophagy in A549 lung cancer cells. Bioorg Med Chem. 17:7085–7092. 2009. View Article : Google Scholar : PubMed/NCBI
28	Holm B, Mellemgaard A, Skov T and Skov BG: Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. J Clin Oncol. 27:4254–4259. 2009. View Article : Google Scholar : PubMed/NCBI
29	Lee SH, Noh KB, Lee JS, et al: Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin. Lung Cancer. 81:102–108. 2013. View Article : Google Scholar : PubMed/NCBI
30	Lord RV, Brabender J, Gandara D, et al: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 8:2286–2291. 2002.PubMed/NCBI
31	Zheng Z, Chen T, Li X, Haura E, Sharma A and Bepler G: DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 356:800–808. 2007. View Article : Google Scholar : PubMed/NCBI
32	Friboulet L, Olaussen KA, Pignon JP, et al: ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med. 368:1101–1110. 2013. View Article : Google Scholar : PubMed/NCBI
33	Lee KH, Min HS, Han SW, et al: ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer. 60:401–407. 2008. View Article : Google Scholar : PubMed/NCBI
34	Harkin DP, Bean JM, Miklos D, et al: Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell. 97:575–586. 1999. View Article : Google Scholar : PubMed/NCBI
35	Potapova O, Haghighi A, Bost F, et al: The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J Biol Chem. 272:14041–14044. 1997. View Article : Google Scholar : PubMed/NCBI
36	Pitterle DM, Kim YC, Jolicoeur EM, Cao Y, O'Briant KC and Bepler G: Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1). Mamm Genome. 10:916–922. 1999. View Article : Google Scholar : PubMed/NCBI
37	Rosell R, Danenberg KD, Alberola V, et al: Spanish Lung Cancer Group: Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 10:1318–1325. 2004. View Article : Google Scholar : PubMed/NCBI
38	Koh Y, Jang B, Han SW, et al: Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J Thorac Oncol. 5:320–325. 2010. View Article : Google Scholar : PubMed/NCBI
39	Burkhart CA, Kavallaris M and Band Horwitz S: The role of β-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta. 1471:O1–O9. 2001.PubMed/NCBI
40	Gan PP, Pasquier E and Kavallaris M: Class III β-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res. 67:9356–9363. 2007. View Article : Google Scholar : PubMed/NCBI